Why Medibank and NIB shares are outperforming today

Premium increases for 2024 have been announced.

| More on:
Health professional working on his laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) may be slipping into the red today, but the same cannot be said for Medibank Private Ltd (ASX: MPL) and NIB Holdings Limited (ASX: NHF) shares.

Both private health insurers are outperforming today with solid gains.

For example, Medibank shares are currently up 2% to $3.76, whereas NIB shares are up 3.5% to $7.85.

Why are Medibank and NIB shares outperforming?

Investors have been buying their shares this morning after the Australian Government gave the green light to premium increases in 2024.

According to a government release, the Albanese Government has approved an average industry premium increase of 3.03%.

Commenting on the increases, the release states:

The Albanese Government has ensured Australians get value for money from their private health insurance, with the average cost of private health insurance premiums rising at a much slower rate than the increase in wages, the age pension and inflation.

The 3.03 per cent increase is well below the annual rise in wages, social security payments and inflation, with wages rising by 4.2 per cent and inflation increasing by 4.1 per cent in 2023, and social security payments increasing in line with inflation.

NIB increases

NIB has been able to score a larger than average increase to its premiums.

An announcement this morning reveals that its 2024 health insurance premiums will rise by an average of 4.1% from 1 April 2024.

Its CEO, Mark Fitzgibbon, notes that the increase reflects the return of hospital and ancillary treatment post COVID-19, and a rise in health and medical treatment costs. He also highlights that claims inflation has moved back to long-term trends and believes it is crucial that insurers are able to price for this.

Mr Fitzgibbon commented:

We're not sitting back passively responding to inflationary pressure by just lifting premiums. We have a range of new measures designed to help members maintain good health as well as reduce out of pocket expenses. Essentially, we're trying to provide members with more value for their premiums.

Medibank will be increasing its premiums by a lower rate of 3.3% for 2024.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor shrugs and holds his hands out.
Healthcare Shares

Down 36% in 2025, should you buy CSL shares today?

A leading investment expert offers his outlook for CSL’s beaten-down share price.

Read more »

Three guys in shirts and ties give the thumbs down.
Healthcare Shares

Why did Macquarie just downgrade CSL shares?

The broker has taken an axe to its valuation of this biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which drug company could pile on almost 30% in gains according to RBC Capital?

This drug company has plenty of irons in the fire, RBC Capital Markets says.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

This ASX 200 stock is charging higher on FDA approval news

This stock is avoiding the market weakness on Monday. Let's find out why.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Key Canadian approval sends 10-bagger biotech's shares higher

This 10-bagger company has just released more good news, with a breakthrough in the Canadian market.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This biotech has lodged a key submission with US regulators

This company has lodged a key submission which will pave the way for sales of its heart failure software in…

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Let’s look at what experts are expecting from the healthcare giant in 2026.

Read more »

medical doctor performing surgery using surgical instruments
Healthcare Shares

Biotech company implants heart device in world first

This biotech company has implanted a heart device as part of a clinical trial looking to open up new markets.

Read more »